# Evergreen Theragnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/evergreen-theragnostics

- Industry: Pharmaceuticals
- Headquarters: Springfield, US
- Website: www.evergreentgn.com/
- Total disclosed funding: $19M
- Latest round: Series A (Apr 27, 2020)
- Investors on record: 1

## About

Founded in 2019 and based in New Jersey, US, Evergreen Theragnostics, Inc. operates as a platform for the pharmaceutical sector, providing antibodies and radiopharmaceutical procedures along with contract development and manufacturing. James Cook (CEO) and Serge Lyashchenko are the co-founders of the company. In April 2024, Evergreen Theragnostics, Inc. raised USD 26 million in venture funding from Petrichor Healthcare Capital Management and LIFTT. In January 2025, Lantheus Holdings, Inc. acquired Evergreen Theragnostics, Inc. from Club Degli Investitori, Petrichor Healthcare Capital Management, and LIFTT, for an upfront payment of USD 250 million and will receive additional payment of USD 752.5 million upon achieving milestones.

The company provides services spanning from discovery to manufacturing, supporting the development and production of medical products. The firm’s key product is OCTEVY™, a kit designed for the preparation of Ga 68 DOTATOC injection. OCTEVY™ holds the advancement in radioactive diagnostic agents. This product develops solutions that enhance medical imaging and diagnostic capabilities and are specifically indicated for use with positron emission tomography (PET). Evergreen Theragnostics’ portfolio of services encompasses radiochemistry development, early-stage manufacturing, late-stage and commercial manufacturing, and an alpha therapy line.

The organization plans to use the April 2024 funding to improve contract development and manufacturing of radiopharmaceutical capabilities and support commercialization.

## Funding rounds

- Series A, Apr 27, 2020, $19M — Club Degli Investitori

## Investors

- Club Degli Investitori (https://capitalatlas.ai/funds/club-degli-investitori) — Series A